A new study reports a beneficial effect of avenciguat — a novel, nitric oxide (NO)-independent, soluble guanylate cyclase (sGC) activator — on albuminuria in patients with chronic kidney disease (CKD). These findings were presented at the 61st European Renal Association Congress in Stockholm.

In patients with CKD, insufficient production of NO leads to impairment of NO–sGC–cyclic guanosine monophosphate signalling in the kidney, resulting in endothelial dysfunction and an increased risk of disease progression. Avenciguat was developed with the aim of restoring endothelial function and thereby slowing loss of kidney function and reducing the risk of cardiovascular disease in patients with CKD.

一项新的研究报告了 avenciguat（一种新型、不依赖一氧化氮 (NO) 的可溶性鸟苷酸环化酶 (sGC) 激活剂）对慢性肾病 (CKD) 患者的白蛋白尿具有有益作用。这些发现在斯德哥尔摩举行的第 61 届欧洲肾脏协会大会上公布。

在 CKD 患者中，NO 生成不足会导致肾脏中 NO-sGC-环磷酸鸟苷信号传导受损，导致内皮功能障碍并增加疾病进展的风险。 Avenciguat 的开发目的是恢复 CKD 患者的内皮功能，从而减缓肾功能的丧失并降低心血管疾病的风险。